McKesson lifts annual profit forecast on plans to focus on high-margin businesses

McKesson (MCK.N) has raised its fiscal 2026 adjusted EPS forecast to $38.05-$38.55 and increased its long-term earnings growth target to 13%-16%, driven by a strategic focus on high-margin oncology and multispecialty businesses. This positive revision, which saw shares rise about 3%, precedes the company's Investor Day where further details on its reorganized segments and the planned separation of its medical-surgical solutions unit are anticipated, against a backdrop of investor concerns about drug pricing.

Analysis

McKesson (MCK) has issued a significant upward revision to its financial outlook, increasing its fiscal 2026 adjusted earnings per share forecast to a range of $38.05-$38.55 and raising its long-term adjusted earnings growth target to 13%-16%. This improved guidance, which prompted an approximate 3% rise in the company's shares, is driven by a strategic reorganization aimed at prioritizing high-margin operations. The newly formed oncology and multispecialty unit is positioned as the primary growth engine, with a projected annual growth rate of 13%-16%, substantially outpacing the 5%-8% growth expected from the traditional North American drug distribution segment. This strategic pivot is supported by targeted M&A, such as the acquisition of a stake in Core Ventures, to bolster its oncology presence. Analyst commentary from firms like Leerink Partners and Evercore ISI has been positive, viewing the pre-investor day announcement as a favorable indicator of future growth. However, investors remain focused on the current operating environment, with specific concerns around drug pricing, and await further details on the planned separation of the medical-surgical solutions unit.

Key Decisions for Investors

• Investors should update their valuation models to reflect the higher long-term adjusted earnings growth target of 13%-16%, as the strategic shift towards high-margin oncology and specialty services provides a clear catalyst for future earnings acceleration.
• Pay close attention to the upcoming investor day for management's detailed execution plan for the new business segments and for commentary on navigating the drug pricing environment, which was noted as a key investor concern.
• Monitor for updates on the planned separation of the medical-surgical solutions unit, as the execution and terms of this transaction represent a significant potential catalyst for value creation or a source of near-term uncertainty.